Effects of Ginkgo biloba extract EGb 761^® in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials

References

• Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Muller WE. 2007. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 56:493–502.
   PubMed Web of Science ®Google Scholar
• Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. 2000a. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12:1882–1890.
   PubMed Web of Science ®Google Scholar
• Bastianetto S, Zheng WH, Quirion R. 2000b. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J Neurochem 74:2268–2277.
   PubMed Web of Science ®Google Scholar
• Berr C, Wancata J, Ritchie K. 2005. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol 15:463–471.
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J. 2009. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev(1):CD003120.
   Google Scholar
• Bornhöft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, et al. 2006. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol 6:56.
   Google Scholar
• Bråne G, Gottfries CG, Winblad B. 2001. The GBS scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord 12:1–14.
   PubMed Web of Science ®Google Scholar
• Caldron PH, Gavrilova SI, Kropf S. 2012. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world. Drug Des Devel Ther 6:53–60.
   Web of Science ®Google Scholar
• Cummings JL. 1997. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48:S10–S16.
   PubMed Web of Science ®Google Scholar
• Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, et al. 2010. National Institutes of Health State-of-the- Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med 153:176–181.
   PubMed Web of Science ®Google Scholar
• Eckert A, Keil U, Kressmann S, Schindowski K, Leutner S, Leutz S, Muller WE. 2003. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 36:S15–S23.
   PubMed Web of Science ®Google Scholar
• Ernst E, Pittler MH. 2005. Ginkgo biloba for vascular dementia and Alzheimer's disease: updated systematic review of doubleblind, placebo-controlled, randomized trials. Perfusion 18:388–392.
   Google Scholar
• Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296.
   PubMed Web of Science ®Google Scholar
• Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. 2012. Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 46:716–723.
   PubMed Web of Science ®Google Scholar
• Hoerr R. 2003. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry 36:S56–S61.
   PubMedGoogle Scholar
• Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O; on behalf of the GSG. 2010. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry 26:1186–1194.
   Google Scholar
• Ihl R, Grass-Kapanke B, Janner M, Weyer G. 1999. Neuropsychometric tests in cross sectional and longitudinal studies – a regression analysis of ADAS - cog, SKT and MMSE. Pharmacopsychiatry 32:248–254.
   PubMed Web of Science ®Google Scholar
• Ihl R, Grass-Kapanke B, Lahrem P, Brinkmeyer J, Fischer S, Gaab N, Kaupmannsennecke C. 2000. Entwicklung und Validierung eines Tests zur Fruherkennung der Demenz mit Depressionsabgrenzung (TFDD). Fortschr Neurol Psychiatr 68:413–422.
   PubMedGoogle Scholar
• Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller H-J, et al. 2011. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias.World J Biol Psychiatry 12:2–32.
   PubMed Web of Science ®Google Scholar
• Janßen IM, Sturtz S, Skipka G, Zentner A, Velasco Garrido M, Busse R. 2010. Ginkgo biloba in Alzheimer's disease: a systematic review. Wien Med Wochenschr 160:539–546.
   PubMedGoogle Scholar
• Kim YS, Nibbelink DW, Overall JE. 1993. Factor structure and scoring of the SKT test battery. J Clin Psychol 49:61–71.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322:1447–1451.
   PubMed Web of Science ®Google Scholar
• Költringer P, Langsteger W, Eber O. 1995. Dose-dependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 15:649–656.
   Google Scholar
• Korczyn AD. 2002. Mixed dementia–the most common cause of dementia. Ann N Y Acad Sci 977:129–134.
   PubMed Web of Science ®Google Scholar
• Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. 2000. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S4–S9.
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. 2005. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65:545–551.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939–944.
   PubMed Web of Science ®Google Scholar
• Mega MS, Masterman DM, O’Connor SM, Barclay TR, Cummings JL. 1999. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56: 1388–1393.
   PubMed Web of Science ®Google Scholar
• Napryeyenko O, Borzenko I, Group G-NS. 2007. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57:4–11.
   Google Scholar
• Ramassamy C, Longpre F, Christen Y. 2007. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?Curr Alzheimer Res 4:253–262.
   PubMed Web of Science ®Google Scholar
• Reisberg B, Finkel S, Overall J, Schmidt-Gollas N, Kanowski S, Lehfeld H, et al. 2001. The Alzheimer's disease activities of daily living international scale (ADL-IS). Int Psychogeriatr 13:163–181.
   PubMed Web of Science ®Google Scholar
• Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. 1993. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250–260.
   PubMed Web of Science ®Google Scholar
• Rosen WG. 1980. Verbal fluency in aging and dementia. J Clin Neuropsychol 2:135–146.
   Google Scholar
• Schneider JA, Arvanitakis Z, Bang W, Bennett DA. 2007. Mixed brain pathologies account for most dementia cases in community- dwelling older persons. Neurology 69:2197–2204.
   PubMed Web of Science ®Google Scholar
• Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. 2005. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2:541–551.
   PubMedGoogle Scholar
• Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. 2005. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 9:1–93, iii–iv.
   Web of Science ®Google Scholar
• Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. 1997. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813–817.
   PubMed Web of Science ®Google Scholar
• Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. 2008. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23:170–177.
   PubMed Web of Science ®Google Scholar
• Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH. 1989. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 37:725–729.
   PubMed Web of Science ®Google Scholar
• Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. 2007. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J 21:2400–2408.
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. 2003. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215–1222.
   PubMed Web of Science ®Google Scholar
• Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. 2010. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10:14.
   PubMed Web of Science ®Google Scholar
• Wimo A, Jonsson L, Gustavsson A, McDaid D, Ersek K, Georges J, et al. 2011. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 26:825–832.
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Aguero-Torres H, von Strauss E. 2003. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17:63–67.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, et al. 2006. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113.
   PubMed Web of Science ®Google Scholar
• Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R, Group GS. 2009. Ginkgo biloba extract EGb 761 , donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 13:183–190.
   PubMed Web of Science ®Google Scholar
• Yoshitake T, Yoshitake S, Kehr J. 2010. The Ginkgo biloba extract EGb 761 and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 159:659–668.
   PubMed Web of Science ®Google Scholar